Brand name · Insulin glargine
Lantus Solostar: adverse event reports filed with FDA
45,715 reports list it as a suspect or interacting product, 2010–2026. Class: Insulin analog.
- 45,715
- reports as suspect product
- 0.2% of all reports · about 2,828 a year
- 4,230
- reports, 12 months to June 2026
- 5,753 in the 12 months before
- 24.6%
- marked serious by the reporter
- 42.7% across the class
- 1%
- record death among outcomes, as reported
- 435 reports · not verified by FDA
45,715 adverse event reports received by FDA list the brand name Lantus Solostar (insulin glargine) as a suspect or interacting product, from May 2010 to June 2026. A further 5,398 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 4,230 reports listed it, down 26% from 5,753 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 2,828 reports a year and 0.2% of the 20,646,523 reports in the database, and 15.8% of the reports for the insulin analog class. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are blood glucose increased (15.8%), inappropriate schedule of product administration (13.1%) and off label use (12.7%). A report can list several reactions, so shares add to more than 100%; 1,118 different terms appear across these reports. Blood glucose increased is recorded in 15.8% of these reports, a smaller share than in the median insulin analog drug (23%).
24.6% of the reports are marked serious by the reporter (42.7% across the class); 1% record death among the outcomes and 7.6% record hospitalisation, as reported. 88.4% of the reports came from consumers, and the largest patient age group is 45 to 64 (27%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Lantus Solostar reports recording the termmedian drug in insulin analog
- Blood glucose increasedraised blood sugar reading15.8%7,220
- Inappropriate schedule of product administrationthe product was taken at the wrong times13.1%5,968
- Off label useused for a purpose or in a way not on the label12.7%5,827
- Product storage errorthe product was stored wrongly11.3%5,157
- Visual impairmentreduced vision7.4%3,386
- Device issuea problem with the device4.4%1,990
- Injection site painpain where the injection was given4.1%1,873
- Product use issuea problem in how the product was used3.5%1,581
- Blood glucose decreasedlow blood sugar reading3.4%1,533
- Drug ineffectivethe medicine did not work as expected2.7%1,235
- Device operational issue2.5%1,145
- Malaisegeneral feeling of being unwell2.4%1,075
- Blood glucose abnormal2.3%1,036
- Product dispensing error1.9%866
- Drug administration errora mistake in giving the medicine1.9%856
- Cerebrovascular accidentstroke1.8%805
- Hypoacusisreduced hearing1.7%786
- Drug dose omissiona dose was missed1.7%782
- Glycosylated haemoglobin increaseda raised HbA1c, the long-term sugar measure1.7%769
- Injection site haemorrhagebleeding where the injection was given1.7%757
- Cataractclouding of the eye lens1.6%735
- Intentional product misusedeliberate use not as intended1.6%725
- Wrong technique in product usage processthe product was used in the wrong way1.5%689
- Hypoglycaemialow blood sugar1.4%631
- Diabetes mellitus inadequate controldiabetes not well controlled1.4%621
- Injection site bruisingbruising where the injection was given1.3%582
- Falla fall1.2%565
Top 30 of 1,118 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 26 drugs in the insulin analog class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 289,293 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 96.1% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Type 2 diabetes mellitus | 25,263 | 55.3% |
| Diabetes mellitus | 7,798 | 17.1% |
| Type 1 diabetes mellitus | 2,681 | 5.9% |
| Blood glucose increased | 2,384 | 5.2% |
| Type ii diabetes mellitus | 73 | 0.2% |
| Gestational diabetes | 44 | 0.1% |
The indication field is filled in by the reporter and is often blank; shares are of all 45,715 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Lantus Solostar reports |
|---|---|---|
| Novolog | 1,937 | 4.2% |
| Humalog | 1,794 | 3.9% |
| Metformin | 1,399 | 3.1% |
| Lantus | 572 | 1.3% |
| Glipizide | 332 | 0.7% |
| Toujeo | 316 | 0.7% |
| Aspirin | 292 | 0.6% |
| Lisinopril | 269 | 0.6% |
| Levemir | 252 | 0.6% |
| Victoza | 251 | 0.5% |
Other products listed in reports where Lantus Solostar is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Lantus Solostar | Insulin analog | All reports |
|---|---|---|---|
| Reports as suspect product | 45,715 | 289,293 | 20,646,523 |
| Share of that pool | — | 15.8% | 0.2% |
| Reports, latest 12 months | 4,230 | — | 1,332,454 |
| Marked serious | 24.6% | 42.7% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 10 | 35 | 91 |
| Hospitalisation recorded, per 1,000 reports | 76 | 186 | 213 |
| Consumer-filed share | 88.4% | 78.7% | 45.8% |
| Top term, share of reports | Blood glucose increased 15.8% | median 23% | 0.9% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the insulin analog class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Humalog | brand | 71,174 | 2,312 | 34.4% |
| Lantus | brand | 39,128 | 3,718 | 63.8% |
| Insulin glargine | generic | 27,994 | 1,923 | 42.8% |
| Toujeo | brand | 15,491 | 1,332 | 24.7% |
| Novolog | brand | 14,477 | 1,576 | 61.8% |
| Levemir | brand | 13,652 | 671 | 54.8% |
| Tresiba | brand | 10,373 | 1,263 | 55.1% |
| Insulin lispro | generic | 8,209 | 1,116 | 45.6% |
| Humalog Mix75/25 | brand | 8,139 | 140 | 23.8% |
| Insulin | generic | 8,135 | 522 | 88.9% |
| Apidra | brand | 3,621 | 86 | 69.2% |
| Insulin aspart | generic | 3,232 | 553 | 88.6% |
| Sterile diluent | generic | 3,221 | 600 | 19.4% |
| Humalog Kwikpen | brand | 3,040 | 169 | 27.5% |
| NovoLog Mix 70/30 | brand | 2,101 | 230 | 65.5% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Lantus Solostar reports
How many adverse event reports has FDA received for Lantus Solostar?
45,715 reports list Lantus Solostar as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 4,230 of them arrived in the latest 12 months. Another 5,398 list it only as a concomitant medication.
What reactions are recorded in Lantus Solostar reports?
blood glucose increased (15.8%), inappropriate schedule of product administration (13.1%), off label use (12.7%), product storage error (11.3%) and visual impairment (7.4%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Lantus Solostar was responsible.
How serious are the reports?
24.6% are marked serious by the reporter. Among the outcomes recorded, 1% of reports include death and 7.6% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (88.4%), other health professional (6.2%) and pharmacist (3.9%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Lantus Solostar rising?
4,230 reports in the 12 months to June 2026, down 26% from 5,753 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Lantus Solostar was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Lantus Solostar?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Lantus Solostar as a suspect or interacting product; reports listing it only as a concomitant medication (5,398) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.